The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion Pharmaceuticals Inc. RXRX, Novavax Inc. NVAX and CRISPR Therapeutics AG CRSP are trending on Thursday. In pre-market trading, RXRX fell 1.42% to $3.45, CRSP dropped 0.15% to $59.72 and NVAX ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Salt Lake City-based biotech Recursion Pharmaceuticals, which is part of the group of companies looking to use AI technology to accelerate drug development, has raised a $121 million Series C ...